Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an emerging treatment for TD2M patients for weight loss that has shown improvements in cardiovascular outcome in those with existing cardiovascular disease (CVD) [6]. This evidence concerns the gene GLP1R and cardiovascular disorder.